With Academic Funding, GSK Looks to Zap Life Into Electroceuticals
This article was originally published in The Gray Sheet
Executive Summary
By seeding exploratory lab work across several biomedical and engineering disciplines, pharma giant GlaxoSmithKline wants to understand how neural signals regulate diseases and eventually to design devices that can alter signals and provide therapeutic benefit.